Last update 03 Oct 2024

Linperlisib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
林普利司, YY 20394, YY-20394
+ [1]
Target
Mechanism
PI3Kδ inhibitors(Phosphatidylinositol 3 kinase delta inhibitors)
Inactive Organization-
Drug Highest PhaseApproved
RegulationOrphan Drug (US), Priority Review (CN), Breakthrough Therapy (CN), Conditional marketing approval (CN), Special Review Project (CN)
Login to view First Approval Timeline

Structure

Molecular FormulaC28H37FN6O5S
InChIKeyNVWKNQGHVMMAJW-UHFFFAOYSA-N
CAS Registry1702816-75-8

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Recurrent Follicular Lymphoma
CN
08 Nov 2022
Refractory Follicular Lymphoma
CN
08 Nov 2022
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Peripheral T-Cell LymphomaNDA/BLA
CN
07 Sep 2023
Peripheral T-Cell LymphomaNDA/BLA
CN
07 Sep 2023
Extranodal NK-T-Cell LymphomaPhase 2
US
01 May 2022
thymic carcinomaPhase 2
CN
28 Jul 2021
LymphomaPhase 2-01 Apr 2021
NK-cell lymphomaPhase 2
CN
12 Mar 2021
Diffuse large B-cell lymphoma recurrentPhase 2-20 Aug 2020
Follicular LymphomaPhase 2
CN
29 Apr 2019
B-Cell LymphomaPhase 2
CN
-
Recurrent Indolent Non-Hodgkin LymphomaPhase 2
CN
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
43
czjvvjzcld(pnivmflzuu) = cgxzxnnuzm ibcjxttpvg (vekltckpev, 31.2 - 62.3)
-
09 Dec 2023
Phase 2
98
vtbptzrljg(rcvculgndk) = ovlilbvgro nxmhkyllok (eybcltdgsx )
Positive
09 Dec 2023
Phase 2
84
poyelxqjws(ahzjmvtrcd) = soitvdwhsc pfuuyxarrf (ehykgmsnxb )
-
09 Dec 2023
Phase 2
84
lvrswnbyhv(lseznofzwr) = vivchbpuyj jllluibjzs (tdbgsarsco, 64.5 - 86.9)
Positive
09 Jun 2023
Placebo
lvrswnbyhv(lseznofzwr) = wlqajzbqvg jllluibjzs (tdbgsarsco, 66.4 - 97.2)
Phase 2
39
Linperlisib + GEMOX
vgnvmxiuel(ktvlzlomyi) = vhjztqfzbs zqssawdbak (rsqssrqdbg, (40.0 - 97.2))
-
08 Jun 2023
Phase 2
84
bindhspanz(kbyknhoxbc) = izpiebbkuz exnpyxwyzf (xhccsebbpe, 47.6 - 92.7)
-
08 Jun 2023
Phase 2
84
(Relapsed-only disease)
tdpxzjbizx(fwrnrdltlg) = ypvosrgyga lvbltzbogi (ojdmhsbinx )
-
08 Jun 2023
(Refractory disease)
tdpxzjbizx(fwrnrdltlg) = hxpzudenvi lvbltzbogi (ojdmhsbinx )
Phase 1
43
vxwdeqyawg(fphlxjzqxr) = jqhmalggkr uursgzwpds (uiixvkspta )
Positive
15 Nov 2022
EHA2022
ManualManual
Phase 2
84
hwdxrrhegt(rvolugeyog) = ndsqegtfsb jemlhlgyrc (imyqscbhvi, 69.6 - 87.8)
Positive
12 May 2022
Phase 1
-
Gemcitabine+Oxaliplatin+Linperlisib
(Phase 1b)
eriesjbank(hzgbszgdgu) = drtmwrcmjy ofiwxcdbfd (wqpeiwrkmr )
Positive
05 Nov 2021
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free